Welcome to our dedicated page for Biorestorative Therapies news (Ticker: BRTX), a resource for investors and traders seeking the latest updates and insights on Biorestorative Therapies stock.
BioRestorative Therapies Inc (BRTX) is a pioneering biotechnology company advancing autologous stem cell therapies for chronic disc/spine conditions and metabolic disorders. This dedicated news hub provides investors and industry professionals with essential updates on clinical developments, regulatory milestones, and corporate announcements.
Access timely information about BRTX-100 clinical trials, metabolic program research, financial disclosures, and strategic partnerships. Our curated collection ensures transparent tracking of progress in regenerative medicine, featuring official press releases and verified news coverage.
Key focus areas include FDA communications, peer-reviewed study results, intellectual property developments, and executive leadership updates. Users benefit from centralized access to critical information for informed decision-making without promotional bias.
Bookmark this page for ongoing updates on BioRestorative Therapies' innovative work in cell-based medical solutions. Check regularly for new developments in non-surgical treatment alternatives and metabolic health innovations.
BioRestorative Therapies (NASDAQ:BRTX) has received a notice of allowance from the Japanese Patent Office for its ThermoStem® platform patent application. The patent covers a method of creating 3D brown adipose derived stem cell aggregates without differentiation medium. This complements their existing patent portfolio and supports potential licensing opportunities. Preclinical studies conducted with the University of Utah School of Medicine showed that ThermoStem® can reduce weight, triglyceride, and blood glucose levels in mice, mirroring the effects of GLP1 drugs. Substantive licensing discussions are ongoing with a commercial stage regenerative medicine company.
BioRestorative Therapies (NASDAQ: BRTX) has regained compliance with Nasdaq Listing Rule 5250(c)(1) following the filing of its Quarterly Report on Form 10-Q for Q1 2024. The clinical-stage company focusing on stem cell therapies reported a significant year-over-year improvement in operating performance. For the quarter ending March 31, 2024, BRTX reported a loss from operations of $4.1 million, a 29% reduction from the $5.8 million loss in Q1 2023. The net loss for Q1 2024 was $2.2 million, or $0.33 per share, compared to $7.2 million, or $1.93 per share, in Q1 2023. Cash used in operating activities was $2.3 million, slightly less than the $2.4 million used in Q1 2023. BioRestorative ended the quarter with $16.4 million in cash, cash equivalents, and marketable securities.
BioRestorative Therapies (NASDAQ:BRTX) is in substantive discussions for a potential license agreement regarding its ThermoStem® metabolic disease program with an undisclosed regenerative medicine company.
ThermoStem® leverages brown adipose derived stem cells (BADSCs) to treat obesity and metabolic disorders.
Preclinical studies with the University of Utah demonstrated significant weight, triglyceride, and blood glucose reductions in mice.
The platform is supported by a comprehensive patent portfolio covering both U.S. and international markets.
While these discussions signal strong interest, no guarantees exist that a deal will be finalized.
BioRestorative Therapies (NASDAQ: BRTX), a clinical-stage company specializing in stem cell-based therapies, announced that CEO Lance Alstodt will attend the Jefferies Global Healthcare Conference from June 5-6, 2024, at the Marriot Marquis in New York. The company will also hold one-on-one meetings with investors during the event.
BioRestorative Therapies (NASDAQ:BRTX) received a non-compliance notice from Nasdaq for not filing its Quarterly Report on Form 10-Q for the quarter ended March 31, 2024, on time. The notice was issued by Nasdaq's Listing Qualifications Department, highlighting a breach of Listing Rule 5250(c)(1), which mandates timely filing of all required periodic reports with the SEC.
The company has until July 22, 2024, to submit a plan to regain compliance. If accepted, Nasdaq may grant an extension of up to 180 days from the original filing due date to regain compliance, potentially extending the deadline to November 18, 2024. The company’s securities will continue to trade on Nasdaq under the symbol 'BRTX.' BioRestorative is making efforts to complete and file the Form 10-Q as soon as possible. This announcement follows Nasdaq's Listing Rule 5810(b), which requires immediate disclosure of such notifications.
BioRestorative Therapies (NASDAQ:BRTX) has entered into a five-year exclusive supply agreement with Cartessa Aesthetics to provide cell-based biologics, targeting the growing aesthetics market. The global aesthetics market, valued at $75.46 billion in 2023, is expected to reach $232.49 billion by 2032. BioRestorative's product, Chronos ExoCR, aims to reduce fine lines and wrinkles, leveraging the company's cell biology expertise and proprietary manufacturing processes. The agreement is expected to generate meaningful revenues and reduce reliance on capital markets. BioRestorative also aims for FDA approval of its bio-cosmeceuticals.
BioRestorative Therapies (NASDAQ: BRTX) provided an update on its first quarter 2024 business performance. Key achievements include advancing its lead clinical program, BRTX-100, with promising preliminary results from a Phase 2 trial, and expanding its preclinical ThermoStem® program targeting obesity. The company secured a commercial agreement with Cartessa Aesthetics for its BioCosmeceuticals line, expected to drive significant revenue growth. Financially, BioRestorative holds $16.4 million in cash and equivalents, offering robust financial flexibility to support its initiatives.
BioRestorative Therapies, Inc. announced the development of an exosome-based biologic program targeting obesity. The candidate aims to complement FDA-approved weight loss drugs, with DMF submission and human studies planned for 2024. The ThermoStem® platform showed promising results in preclinical studies, potentially leading to big pharma partnerships.
BioRestorative Therapies, Inc. will report its first quarter 2024 financial results on May 14, 2024, after market close. The company will discuss a new commercial agreement and provide updates on its Phase 2 clinical trial in Spine and preclinical development program in Obesity. CEO Lance Alstodt will host the quarterly conference call to review the financial results and business progress.
BioRestorative Therapies, Inc. (
FAQ
What is the current stock price of Biorestorative Therapies (BRTX)?
What is the market cap of Biorestorative Therapies (BRTX)?
